Skip to main content
BCAB logo

BCAB · BioAtla, Inc.

Track BCAB — free
$3.09 -0.36 (-10.43%) At close · Aug 14
Market Cap
$5.15M
Shares
1.67M

BioAtla, Inc. Earnings Call Transcripts

Every quarterly earnings call for BioAtla, Inc. (BCAB) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Earnings call
FY25 · Q3
2025-11-13
BioAtla, Inc. Q3 FY2025 Earnings Call
Confident tone Phase 3 OSV Registrational Trial (OPSCC) Market Opportunity / Commercial Prospects Mecbotamab Vedotin (MEK-V) / MECD Program
Diluted EPS
$-13.50
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
BioAtla, Inc. Q2 FY2025 Earnings Call
Positive tone BA3182 EPCAM CD3 T-cell engager OSV (CAB-AXL ADC) head and neck cancer Conference presentations and data readouts
Diluted EPS
$-15.99
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2025-05-07
Citizens Life Sciences Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q1
2025-05-06
BioAtla, Inc. Q1 FY2025 Earnings Call
Positive tone Mecbotamab Vedotin (CAB-AXL-ADC) in mKRAS NSCLC and sarcoma Corporate partnerships and deal-making Evalstotug (CAB-CTLA-4) in melanoma
Diluted EPS
$-13.16
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-27
BioAtla, Inc. Q4 FY2024 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
BioAtla, Inc. Q3 FY2024 Earnings Call
Confident tone Ozuriftamab vedotin (CAB-ROR2-ADC) in head and neck cancer Evalstotug (CAP CTLA-4) in melanoma Cash runway and financing strategy
Diluted EPS
$-11.00
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
BioAtla, Inc. Q2 FY2024 Earnings Call
Positive tone Evalstotug (CAB CTLA-4 antibody) safety and efficacy Ozuriftamab vedotin (CAB-ROR2-ADC) in head and neck cancer Mecbotamab vedotin (CAB-AXL-ADC) in NSCLC and KRAS
Diluted EPS
$-22.00
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
BioAtla, Inc. Q1 FY2024 Earnings Call
Positive tone CAB-ROR2-ADC (ozuriftamab vedotin) in head and neck cancer CAB CTLA-4 antibody (evalstotug) dose escalation Nectin-4 ADC with carbohydrate linker
Diluted EPS
$-24.00
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-26
BioAtla, Inc. Q4 FY2023 Earnings Call
Confident tone BA3071 CAB-CTLA-4 antibody BA3021 CAB-ROR2-ADC BA3011 CAB-AXL-ADC
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
BioAtla, Inc. Q3 FY2023 Earnings Call
Revenue
$
Diluted EPS
$-35.00
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
BioAtla, Inc. Q2 FY2023 Earnings Call
Revenue
$
Diluted EPS
$-37.50
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
BioAtla, Inc. Q1 FY2023 Earnings Call
Revenue
$
Diluted EPS
$-29.00
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-23
BioAtla, Inc. Q4 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
BioAtla, Inc. Q3 FY2022 Earnings Call
Revenue
$
Diluted EPS
$-34.50
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
BioAtla, Inc. Q2 FY2022 Earnings Call
Revenue
$
▼ 100% YoY
Diluted EPS
$-38.50
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
BioAtla, Inc. Q1 FY2022 Earnings Call
Revenue
$
Diluted EPS
$-32.50
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–16 of 16 earnings calls
Key facts CIK 1826892 CUSIP 09077B203 13F (30d) 21 filings 21 filers Visit website Investor relations